Disintegrin and metalloproteinase domain-containing protein 11 (ADAM11)

Disintegrin and metalloproteinase domain-containing protein 11 (ADAM11) is a member of the ADAM (a disintegrin and metalloprotease) family, encoded by the ADAM11 gene. Unlike many ADAMs, ADAM11 lacks proteolytic activity (non-catalytic) and functions primarily in protein-protein interactions and cell signaling regulation. ADAM11 is membrane-anchored and implicated in cell adhesion, migration, neural development, spatial learning, motor coordination, and nociceptive pain response[4]. It has an established role as a regulator of Wnt and BMP4 signaling pathways, impacting embryonic neural crest development and proliferation[2]. ADAM11 is considered a tumor suppressor candidate in breast cancer due to its genomic location and observed expression patterns[3][4]. Decreased ADAM11 expression is found in many solid tumors, correlating with upregulation of Wnt signaling and proliferation markers (CyclinD1); in neuroblastoma, increased ADAM11 expression correlates with stem cell marker profiles[2]. There are currently no known drugs that directly target ADAM11, and its modulation presents significant safety concerns due to its role in neural development and tissue homeostasis.

Other names

Disintegrin and metalloproteinase domain-containing protein 11ADAM11MDCADAM 11Metalloproteinase-like, disintegrin-like, and cysteine-rich proteinMDC protein